We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Developing a COVID-19 Vaccine: Cobra Biologics Part of ChAdOx1 Consortium

Product News   Apr 01, 2020

 
Developing a COVID-19 Vaccine: Cobra Biologics Part of ChAdOx1 Consortium
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News

Advent has manufactured 13,000 doses of the novel COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222) for use in the Phase 2/3 clinical trial COV002 by the University of Oxford.

READ MORE

Phase I/II Clinical Trial of COVID-19 Vaccine Begins

Product News

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

READ MORE

Avacta and Medusa19: Distribution Agreement for COVID-19 Antigen Test

Product News

Avacta has entered into an exclusive distribution agreement with Medusa19 for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen.

READ MORE

Like what you just read? You can find similar content on the communities below.

Biopharma Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE